Current issue
Archive
About the Journal
About us
Aims and Scope
Indexing and Abstracting
Editorial Office
Open Access Policy
Publication Ethics
Contact
For Authors
Editorial Policy
Peer Review Policy
Manuscript Preparation Guidelines
Copyright & Licensing
Publication Fees
Fast-Track Paper Publication Option
Conflict Interest Guidance
Submit an Article
Special Issues
News & Editorials
“Fake,” “Predatory,” and “Pseudo” Journals: Charlatans Threatening Trust in Science
Shifting the Journal submission-review system to the Editorial System Manuscript December 27, 2017.
ORIGINAL ARTICLE
Serum bilirubin levels are negatively associated with atherogenic lipids in Saudi subjects with type 2 diabetes: A pilot study
1
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, SAUDI ARABIA
Online publication date: 2023-01-01
Publication date: 2023-03-01
Electron J Gen Med 2023;20(2):em444
KEYWORDS
ABSTRACT
Background:
Recent research has demonstrated the possible relevance of bilirubin in metabolic and cardiovascular disorders. Lipid abnormalities are a major problem that is related with an increased risk of cardiovascular disease in diabetics. This study examined the relationship between serum bilirubin and direct bilirubin concentrations and atherogenic lipids in patients with type 2 diabetes (T2DM).
Methods:
This cross-sectional included 67 patients with type 2 diabetes and 39 matched healthy control. The lipid profile, including total cholesterol, HDL-C, and TG levels, fasting blood glucose, total bilirubin, direct bilirubin, ALT, AST, and ALP were measured using a dimension EXL clinical chemistry analyzer (Siemens Healthcare Diagnostics). Cholesterol in VLDL, LDL, and sdLDL were calculated from standard lipid assay results by the equations of Sampson et al.
Results:
This cross-sectional included 67 patients with type 2 diabetes and 39 matched healthy control. The lipid profile, including total cholesterol, HDL-C, and TG levels, fasting blood glucose, total bilirubin, direct bilirubin, ALT, AST, and ALP were measured using a dimension EXL clinical chemistry analyzer (Siemens Healthcare Diagnostics). Cholesterol in VLDL, LDL, and sdLDL were calculated from standard lipid assay results by the equations of Sampson et al.
Conclusions:
A significant negative association was found between serum bilirubin levels and direct serum bilirubin with atherogenic lipids, suggesting that serum bilirubin may protect T2DM patients from development of cardiovascular disease. These findings indicate the need for additional research in a large cohort.
Recent research has demonstrated the possible relevance of bilirubin in metabolic and cardiovascular disorders. Lipid abnormalities are a major problem that is related with an increased risk of cardiovascular disease in diabetics. This study examined the relationship between serum bilirubin and direct bilirubin concentrations and atherogenic lipids in patients with type 2 diabetes (T2DM).
Methods:
This cross-sectional included 67 patients with type 2 diabetes and 39 matched healthy control. The lipid profile, including total cholesterol, HDL-C, and TG levels, fasting blood glucose, total bilirubin, direct bilirubin, ALT, AST, and ALP were measured using a dimension EXL clinical chemistry analyzer (Siemens Healthcare Diagnostics). Cholesterol in VLDL, LDL, and sdLDL were calculated from standard lipid assay results by the equations of Sampson et al.
Results:
This cross-sectional included 67 patients with type 2 diabetes and 39 matched healthy control. The lipid profile, including total cholesterol, HDL-C, and TG levels, fasting blood glucose, total bilirubin, direct bilirubin, ALT, AST, and ALP were measured using a dimension EXL clinical chemistry analyzer (Siemens Healthcare Diagnostics). Cholesterol in VLDL, LDL, and sdLDL were calculated from standard lipid assay results by the equations of Sampson et al.
Conclusions:
A significant negative association was found between serum bilirubin levels and direct serum bilirubin with atherogenic lipids, suggesting that serum bilirubin may protect T2DM patients from development of cardiovascular disease. These findings indicate the need for additional research in a large cohort.
REFERENCES (36)
1.
Creeden JF, Gordon DM, Stec DE, Hinds Jr TD. Bilirubin as a metabolic hormone: The physiological relevance of low levels. Am J Physiol Endocrinol Metab. 2021;320(2):E191-207. https://doi.org/10.1152/ajpend... PMid:33284088 PMCid:PMC8260361.
2.
Boon AC, Hawkins CL, Coombes JS, Wagner KH, Bulmer AC. Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation in physiologically relevant hyperbilirubinemic serum. Free Radic Biol Med. 2015;86:259-68. https://doi.org/10.1016/j.free... PMid:26057938.
3.
Wei Y, Liu C, Lai F, et al. Associations between serum total bilirubin, obesity and type 2 diabetes. Diabetol Metab Syndr. 2021;13(1):143. https://doi.org/10.1186/s13098... PMid:34876211 PMCid:PMC8650363.
4.
Zhong P, Sun D, Wu D, Liu X. Total bilirubin is negatively related to diabetes mellitus in Chinese elderly: A community study. Ann Transl Med. 2019;7(18):474. https://doi.org/10.21037/atm.2... PMid:31700910 PMCid:PMC6803226.
5.
Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: A global perspective. Endocrinol Metab ClinNorth Am. 2021;50(3):337-55. https://doi.org/10.1016/j.ecl.... PMid:34399949.
6.
Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diab... PMid:34879977.
7.
Thambiah SC, Lai LC. Diabetic dyslipidaemia. Pract Lab Med. 2021;26:e00248. https://doi.org/10.1016/j.plab... PMid:34368411 PMCid:PMC8326412.
8.
Dullaart RPF, de Vries R, Lefrandt JD. Increased large VLDL and small LDL particles are related to lower bilirubin in type 2 diabetes mellitus. Clin Biochem. 2014;47(16-17):170-5. https://doi.org/10.1016/j.clin... PMid:25149194.
9.
Kanonidou C. Small dense low-density lipoprotein: Analytical review. Clin Chim Acta. 2021;520:172-8. https://doi.org/10.1016/j.cca.... PMid:34118239.
10.
Qin S. LDL and HDL oxidative modification and atherosclerosis. Adv Exp Med Biol; 2020;1276:157-69. https://doi.org/10.1007/978-98... PMid:32705599.
11.
Stahel P, Xiao C, Hegele RA, Lewis GF. The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes. Can J Cardiol. 2018;34(5):595-604. https://doi.org/10.1016/j.cjca... PMid:29459241.
12.
Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev. 2017;2017:1273042. https://doi.org/10.1155/2017/1... PMid:28572872 PMCid:PMC5441126.
13.
Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55. https://doi.org/10.3389/fphar.... PMid:22493581 PMCid:PMC3318228.
14.
Stalenhoef AFH, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol. 2008;19(4):355-61. https://doi.org/10.1097/MOL.0b... PMid:18607182.
15.
Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: Clinical significance and therapeutic approaches. Nutrients. 2013;5(3):928-48. https://doi.org/10.3390/nu5030... PMid:23507795 PMCid:PMC3705327.
16.
Sampson M, Wolska A, Warnick R, Lucero D, Remaley AT. A new equation based on the standard lipid panel for calculating small dense low-density lipoprotein-cholesterol and its use as a risk-enhancer test. Clin Chem. 2021;67(7):987-97. https://doi.org/10.1093/clinch... PMid:33876239 PMCid:PMC8260186.
17.
Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40(1):18-23. https://doi.org/10.1093/clinch... PMid:8287538.
18.
Alouffi S, Khan MWA, Alotabi N, et al. Correlations between direct and calculated low-density lipoprotein cholesterol measurements in children and adolescents. J Clin Lab Anal. 2020;34(6):e23236. https://doi.org/10.1002/jcla.2... PMid:32125729 PMCid:PMC7307368.
19.
Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: From mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020;159:4-33. https://doi.org/10.1016/j.addr... PMid:32730849.
20.
Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-99. https://doi.org/10.1007/s00125... PMid:25725623 PMCid:PMC4392164.
21.
Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. https://doi.org/10.1016/S0140-....
22.
Superko H, Garrett B. Small dense LDL: Scientific background, clinical relevance, and recent evidence still a risk even with ‘Normal’ LDL-C levels. Biomedicines. 2022;10(4):829. https://doi.org/10.3390/biomed... PMid:35453579 PMCid:PMC9025822.
23.
Choi CU, Seo HS, Lee EM, et al. Statins do not decrease small, dense low-density lipoprotein. Tex Heart Inst J. 2010;37(4):421-8.
24.
Khoei NS, Wagner K-H, Sedlmeier AM, Gunter MJ, Murphy N, Freisling H. Bilirubin as an indicator of cardiometabolic health: A cross-sectional analysis in the UK Biobank. Cardiovasc Diabetol. 2022;21(1):54. https://doi.org/10.1186/s12933... PMid:35436955 PMCid:PMC9017025.
25.
Adin CA. Bilirubin as a therapeutic molecule: Challenges and opportunities. Antioxidants (Basel). 2021;10(10):1536. https://doi.org/10.3390/antiox... PMid:34679671 PMCid:PMC8532879.
26.
Stec DE, John K, Trabbic CJ, et al. Bilirubin binding to PPARα inhibits lipid accumulation. PLoS One. 2016;11(4):e0153427. https://doi.org/10.1371/journa... PMid:27071062 PMCid:PMC4829185.
27.
Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med. 2008;121(9):781-8.e1. https://doi.org/10.1016/j.amjm... PMid:18724968 PMCid:PMC2596911.
28.
Novotný L, Vítek L. Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228(5):568-71. https://doi.org/10.1177/153537... PMid:12709588.
29.
Kunutsor SK, Bakker SJL, Gansevoort RT, Chowdhury R, Dullaart RPF. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35(3):716-24. https://doi.org/10.1161/ATVBAH... PMid:25593130.
30.
Maruhashi T, Kihara Y, Higashi Y. Bilirubin and endothelial function. J Atheroscler Thromb. 2019;26(8):688-96. https://doi.org/10.5551/jat.RV... PMid:31270300 PMCid:PMC6711845.
31.
Ikeda N, Inoguchi T, Sonoda N, et al. Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Diabetologia. 2011;54(8):2183-91. https://doi.org/10.1007/s00125... PMid:21614569.
32.
Wagner K-H, Khoei NS, Hana CA, et al. Oxidative stress and related biomarkers in Gilbert’s syndrome: A secondary analysis of two case-control studies. Antioxidants (Basel). 2021;10(9):1474. https://doi.org/10.3390/antiox... PMid:34573106 PMCid:PMC8472792.
33.
Peters AL. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes. 2008;26(1):3-7. https://doi.org/10.2337/diacli....
34.
Ram N, Ahmed B, Hashmi F, Jabbar A. Importance of measuring non-HDL cholesterol in type 2 diabetes patients. J Pak Med Assoc. 2014;64(2):124-8.
35.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143-421. https://doi.org/10.1161/circ.1... PMid:12485966.
36.
Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106(20):2526-9. https://doi.org/10.1161/01.CIR... PMid:12427645.
Share
RELATED ARTICLE
| eISSN: | 2516-3507 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
